1. Current Management and Future Options for Tardive Dyskinesia

2. This program will include a discussion of off-label treatments and investigational agents not approved by the FDA for use in the US, as well as data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Tardive Dyskinesia

4. Prevalence of TD Has Not Declined

5. Prevention of TD

6. Treatment Initiation for TD

7. Initial Steps in Treating TD

8. Resolution of TD With Antipsychotic Discontinuation

9. Switching Antipsychotic Agents

10. AAN Guidelines

11. Double-Blind Trials With Amantadine or Clonazepam for TD

12. Extract of Ginkgo Biloba

13. Tetrabenazine

14. VMAT2

15. Trials of Tetrabenazine for TD

16. Tetrabenazine Limitations

17. Valbenazine

18. Valbenazine for TD KINECT 3: Phase 3 Trial Design

19. Valbenazine for TD KINECT 3: Phase 3 Trial Results

20. Valbenazine for TD KINECT 3: Phase 3 Extension

21. Deutetrabenazine

22. ARM-TD Trial Design

23. ARM-TD Trial Results

24. AIM-TD

25. TD Remains a Problem

26. The Dopamine System and TD

27. Conclusions

28. Abbreviations

29. Abbreviations (cont)